Structural–Functional Characteristics, Production Technologies, and Application Progress of Thrombin
Structural–Functional Characteristics, Production Technologies, and Application Progress of Thrombin
Thrombin is a central serine protease in the coagulation cascade. It not only drives fibrin clot formation and promotes platelet activation, but—under specific cofactor conditions—also mediates anticoagulant pathways and cell signaling, thereby exhibiting marked pleiotropy in physiological hemostasis, inflammatory responses, and tissue repair. Industrialization and clinical translation of thrombin products depend critically on controllable manufacturing processes and rigorous quality systems. In particular, a systematic balance must be achieved among activity, purity, impurity profiles, and biosafety to meet the requirements for consistency and traceability across diverse scenarios, including clinical hemostasis, in vitro diagnostics, and biomedical research.
Keywords: thrombin; serine protease; recombinant production; quality control; topical hemostasis
I. Molecular Structure and Biological Functions of Thrombin
1.1 Molecular structural features
Thrombin (EC 3.4.21.5) is generated from prothrombin via limited proteolysis catalyzed by the prothrombinase complex composed of factors Xa and Va, Ca²⁺, and phospholipids. Mature thrombin is a disulfide-linked two-chain molecule consisting of an A chain and a B chain, with a molecular mass of approximately 37 kDa. Using human α-thrombin as a representative example, the A chain contains ~36 amino acid residues and the B chain contains ~259 residues. The B chain adopts a canonical chymotrypsin-like fold and contains the catalytic triad His57, Asp102, and Ser195 (chymotrypsin numbering), forming the structural basis for substrate recognition and cofactor interactions.
Multiple conformationally adaptable loop regions surround the active site. Thrombin also presents several functional surface sites (often termed exosites/exosite-binding regions), enabling differential substrate selectivity and signaling outputs under distinct substrate and cofactor contexts. Multisite interactions together with conformational plasticity constitute the structural foundation for thrombin’s multifunctionality.
1.2 Core biological functions
Thrombin occupies a pivotal node in hemostasis and thrombosis while also exerting homeostatic regulatory and cellular signaling effects.
1.2.1 Fibrin formation and clot stabilization
Thrombin cleaves specific Arg–Gly peptide bonds in fibrinogen, releasing fibrinopeptides and generating fibrin monomers that polymerize into a fibrin network. Thrombin also activates factor XIII, promoting fibrin crosslinking and enhancing clot stability and resistance to fibrinolysis.
1.2.2 Platelet activation and thrombus growth
Through protease-activated receptors (PAR-1, PAR-4, etc.), thrombin triggers platelet activation, inducing adhesion, aggregation, and granule release. This promotes hemostatic plug formation and spatial amplification of coagulation reactions.
1.2.3 Positive-feedback amplification within the coagulation cascade
Thrombin activates coagulation factors V, VIII, and XI, establishing positive-feedback loops that accelerate clot formation. While beneficial for rapid hemostasis, this mechanism can increase thrombotic risk under pathological conditions.
1.2.4 Anticoagulation and homeostatic regulation
On the endothelial surface, thrombin binding to thrombomodulin alters thrombin’s substrate specificity and promotes protein C activation. Activated protein C inactivates factors Va and VIIIa, contributing to anticoagulant regulation and maintaining the balance between procoagulant and anticoagulant pathways.
1.2.5 Inflammation- and tissue-repair–related effects
Via PAR-dependent signaling, thrombin modulates endothelial adhesion molecule expression, cell migration, and extracellular matrix remodeling, and influences immune cell recruitment and tissue repair. The direction and magnitude of these effects depend on the microenvironment, receptor expression profiles, and cofactor status.
II. Research Progress in Thrombin Production Technologies
Thrombin manufacturing routes mainly include plasma-derived production and recombinant biotechnological production. These approaches differ substantially in raw-material availability, impurity profiles and pathogen risks, process controllability, and lot-to-lot consistency.
2.1 Conventional plasma extraction
Animal plasma (bovine, porcine, etc.) or human plasma is used as the starting material to isolate prothrombin, which is then activated to thrombin. A typical process comprises pretreatment, enrichment/purification, activation, polishing, and formulation (e.g., lyophilization).
2.1.1 Raw-material pretreatment and anticoagulation
Blood cell components are separated at low temperature, and anticoagulants such as citrate are added. Temperature and hold time are controlled to reduce proteolysis and loss of activity.
2.1.2 Prothrombin separation and enrichment
Salting-out fractionation and cold ethanol fractionation are commonly used for initial enrichment, followed by ion-exchange chromatography, gel filtration, and affinity chromatography (e.g., benzamidine ligand systems) for further purification.
2.1.3 Activation conversion and removal of residual activators
Conversion may be achieved using the prothrombinase complex or specific proteases. Reaction parameters (pH, ionic strength, temperature, and time) must be carefully controlled, and chromatography-based steps are then applied to remove residual activators and unconverted precursors, thereby reducing risks of nonspecific proteolysis.
2.1.4 Biosafety control
For human plasma-derived products, a systematic viral safety strategy is required (donor screening/testing + in-process removal/inactivation + validation). For animal-derived products, attention should be paid to heterologous protein–related immunogenic risks and raw-material traceability.
This route benefits from mature processing know-how, but is limited by reliance on plasma resources, batch variability, and higher costs associated with biosafety management.
2.2 Modern biotechnological production
Recombinant routes obtain thrombin precursors/domains via heterologous expression, followed by in vitro activation and purification to yield functional thrombin, potentially reducing dependence on plasma resources and improving standardization.
2.2.1 Prokaryotic expression systems
Escherichia coli is widely used due to cost and scale-up advantages. However, lacking a eukaryotic folding and modification environment, products often accumulate as inclusion bodies, necessitating denaturation/solubilization and in vitro refolding to form correct disulfide bonds and recover active conformations, followed by in vitro activation to generate active thrombin. Key bottlenecks include refolding efficiency, aggregation control, activity recovery, and impurity profile management.
2.2.2 Eukaryotic expression systems
Yeast (e.g., Pichia pastoris) and mammalian cells (e.g., CHO, HEK293) can improve correct folding and disulfide bond formation and provide certain post-translational modifications, producing material that more closely resembles native conformation and functional characteristics. Yeast systems often offer higher expression levels and scalability, whereas mammalian systems have advantages in clinical-grade consistency, control of modification patterns, and reduced immunogenic risk—at the expense of higher cost and process complexity. System selection should be guided by intended use and the quality target product profile.
2.2.3 Emerging production and molecular engineering strategies
Cell-free protein synthesis offers high controllability and rapid iteration, but is still primarily used for research and proof-of-concept purposes. Protein engineering via site-directed mutagenesis of exosites, substrate-recognition regions, or stability-associated residues can optimize activity spectra, specificity, and stability. Such modifications should be accompanied by assessment of off-target proteolysis risks and immunogenicity risks, and integrated into systematic quality studies and validation.
III. Quality Control Technologies and Standardization Considerations
Thrombin quality control should establish a fit-for-purpose indicator system encompassing identity confirmation, activity characterization, purity/impurity profiling, biosafety, and stability, aligned with intended use and route of administration.
3.1 Key quality attributes and analytical methods
3.1.1 Activity assays
Thrombin activity is commonly measured using clotting-based assays and chromogenic substrate assays. Clotting assays use fibrinogen as the substrate and convert clotting time relative to a reference standard into activity units; they are highly functionally relevant but sensitive to substrate quality and assay conditions. Chromogenic assays use synthetic substrates (e.g., S-2238) and quantify absorbance changes; they provide good sensitivity and reproducibility and are readily standardized, making them suitable for in-process control and release testing. Both approaches require clearly defined standard traceability and validated methods to ensure comparability.
3.1.2 Purity testing
Purity control constrains levels of host or contaminating proteins, degradation fragments, and aggregates. SDS-PAGE supports rapid qualitative evaluation, whereas HPLC-based methods are critical for quantitative control. Commonly used approaches include SEC-HPLC for aggregate/molecular-size distribution, RP-HPLC for degradation products and microheterogeneity, and, when necessary, IEX-HPLC for charge variants. Purity limits should be tiered by intended use and aligned with stability study outcomes.
3.1.3 Impurity control
Impurity control should cover product-related impurities and process-related impurities. For recombinant products, host cell proteins (HCP) and residual nucleic acids should be controlled (typically by ELISA and qPCR, respectively). Processes involving activation steps should control residual activators and unconverted precursors. Endotoxin is commonly measured by LAL-based methods or equivalent assays; limits should match route of administration and exposure level. For plasma-derived products, a systematic viral safety strategy with validation is required rather than reliance solely on marker testing.
3.1.4 Safety testing
Safety evaluation should align with regulatory requirements and intended use, typically including endotoxin/pyrogen-related controls, sterility or bioburden controls (as applicable), and immunogenicity-related risk considerations under defined contexts, along with general safety requirements. Release tests and acceptance criteria should be based on the pharmacopeial and regulatory requirements of the target market.
3.2 Domestic and international quality standards
Quality standards for thrombin products are generally defined by pharmacopeial requirements and regulatory registration frameworks. USP, EP, and the Chinese Pharmacopoeia specify activity unit definitions, test methods, purity and impurity limits, and biosafety requirements, and are updated over time. In addition to pharmacopeial release testing, clinical-grade products typically require identification of critical quality attributes (CQAs), validation of process consistency, stability studies, and lifecycle change control within registration frameworks to ensure lot-to-lot consistency and controlled risk.
IV. Application Areas of Thrombin
4.1 Clinical applications
Thrombin is primarily used for topical hemostasis and as a surgical adjunct, often in combination with carrier materials or fibrinogen-based systems to enhance local clot formation.
4.1.1 Topical hemostasis
Used for oozing wounds, small-vessel bleeding, and mucosal/superficial bleeding by locally catalyzing fibrin formation for rapid sealing. Formulations include lyophilized powder, solutions, gels, and composites with carriers such as sponges/gelatin materials.
4.1.2 Surgical adjunct hemostasis and tissue sealing
Used for bleeding control at large surgical wound surfaces and anastomotic sites, and as a component of fibrin sealant systems. These applications impose higher requirements for consistency, impurity profiling, and local safety.
4.2 Biomedical research and biotechnology applications
4.2.1 Mechanistic and signaling studies
Applied in studies of the coagulation cascade, platelet activation, endothelial function, and inflammatory signaling; also used to build in vivo/in vitro thrombosis models for antithrombotic drug screening and mechanistic validation.
4.2.2 Tool enzyme applications
Thrombin recognizes and cleaves specific sequences (e.g., LVPR↓GS) and is widely used to remove affinity tags or process recombinant proteins. Reaction conditions should be optimized, and residual thrombin should be removed during purification to reduce downstream proteolysis risk.
4.3 In vitro diagnostics and reagent industry
Thrombin is used in coagulation assay reagents, calibrators, and quality controls, integrated with coagulation analyzer systems. Key considerations include traceability of activity units, batch-to-batch consistency and stability, and controlled impurity and microbiological attributes.
V. Aladdin-Related Products
Catalog No. | Product Name | Grade and Purity | Applicable Scenarios | Usage Notes |
Thrombin | from human plasma | In vitro coagulation/fibrinogen conversion assays; enzymatic activity evaluation | Dilute in the assay system and prepare fresh before use; aliquot for storage and avoid repeated freeze–thaw cycles | |
Thrombin human | UltraBio™；≥95%(SDS-PAGE)；recombinant；expressed in HEK 293 cells；aqueous solution | In vitro coagulation-related assays; enzyme studies requiring higher purity | Aqueous solutions can typically be diluted directly; keep cold throughout; aliquot to minimize freeze–thaw cycles | |
Technical Grade Bovine Thrombin | EnzymoPure™；50,000–150,000 units/g；powder | Process development/scale-up verification; raw-material evaluation and method development (non-clinical use) | Reconstitute with the experimental buffer before use; after reconstitution, sterile-filter if a sterile system is required and aliquot for storage | |
Technical Grade Porcine Thrombin | EnzymoPure™；50,000–150,000 units/g；powder | Process development/scale-up verification; raw-material evaluation and method development (non-clinical use) | Match reconstitution conditions as closely as possible to the activity assay system; avoid prolonged coexistence with strong denaturants/inhibitors | |
Liquid — High Purity Thrombin (> 2700 U/mg Protein) | EnzymoPure™；＞500 units/ml | Enzymatic assays requiring rapid loading of a liquid formulation; rapid preparation of fibrin gels | Mix gently before use to avoid foaming; perform a concentration-gradient pilot to determine the optimal final working level | |
Australian/New Zealand Sourced Technical Grade Bovine Thrombin | EnzymoPure™；50,000–150,000 units/g；powder | Technical-grade raw-material screening; process and QC method development (non-clinical use) | Same as similar powder products: aliquot after reconstitution; minimize repeated temperature cycling during storage and transport | |
High Purity Bovine Thrombin (> 1500 U/Mg Protein) | EnzymoPure™；＞200,000 units/g；powder | Enzyme studies requiring higher specific activity; systems more sensitive to contaminating proteins | High specific activity typically allows lower dosing; run a small-scale titration first to avoid nonspecific effects due to overdose | |
High Purity Bovine Thrombin (> 2200 U/Mg Protein) | EnzymoPure™；＞200,000 units/g；powder | Enzyme studies requiring very high specific activity; systems requiring lower background protein | Similar to H419639: prioritize dose titration; aliquot and record usage per thaw to support traceability |
Thrombin’s multisite interactions and conformational plasticity determine its multiple roles in procoagulation, anticoagulation, and cellular signaling, and likewise necessitate an integrated “structure–function–safety” technical strategy for production and quality control. For high-demand scenarios such as clinical hemostasis and in vitro diagnostics, future work should prioritize improving the robustness and scalability of recombinant expression and in vitro activation/purification, establishing high-resolution structural characterization and impurity profiling systems, and developing standardized formulation and use specifications centered on local delivery and material composites to enable stable, traceable, and verifiable quality delivery across broader applications.
Aladdin: https://www.aladdinsci.com/